Type 2 Diabetes is a recurring topic in our peptide coverage. This hub collects every article tagged Type 2 Diabetes, newest first, each evidence-graded and tied to real, verifiable sources.
A clinical monograph on orforglipron — the first oral, non-peptide small-molecule GLP-1 receptor agonist, FDA-approved as Foundayo in 2026 for chronic weight management, with Grade A Phase 3 RCT evidence.
A clinical monograph on retatrutide (LY3437943) — Eli Lilly's investigational triple GIP/GLP-1/glucagon agonist with the largest pharmacologic weight loss reported to date, graded A on human Phase 3 RCTs, but FDA-unapproved and WADA-prohibited as of mid-2026.
A clinical monograph on mazdutide (IBI362 / LY3305677) — the first GLP-1/glucagon dual receptor agonist, backed by completed Phase 3 RCTs for obesity and type 2 diabetes, approved in China but investigational in the US.
A clinical monograph on lixisenatide (Adlyxin/Lyxumia) — the short-acting, exendin-4-derived GLP-1 receptor agonist for type 2 diabetes, with a large RCT base, proven cardiovascular safety, and an emerging Parkinson's signal.
A clinical monograph on liraglutide — the once-daily GLP-1 receptor agonist sold as Victoza and Saxenda. Grade A human RCT evidence for glycemic control, weight loss, and reduced cardiovascular death.
A clinical monograph on exenatide — the first-in-class GLP-1 receptor agonist (synthetic exendin-4) — with a focus on its Grade A pediatric type 2 diabetes evidence, mechanism, dosing from the literature, safety, and 2026 regulatory status.
A clinical monograph on dulaglutide (Trulicity) — the once-weekly GLP-1-Fc fusion biologic with Grade A human RCT evidence for glycemic control and a 12% cardiovascular event reduction.
Type 2 Diabetes is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged Type 2 Diabetes, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.